pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Sanofi ($SNY) · news · pharmadog
← back to Sanofi
News mentioning $SNY
221
stories
Aug 11, 26
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
biopharma dive
Aug 11, 26
Epicrispr raises $90M to rewrite treatment of rare muscle disease
fiercebiotech
Aug 10, 26
STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more
stat
Aug 10, 26
Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
fiercebiotech
Aug 9, 26
STAT+: A shortage of two Sanofi medicines for Pompe disease rattles patients
stat
Aug 6, 26
Chutes & Ladders—BioNTech brings in Sobi CEO
fiercebiotech
Aug 6, 26
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
Aug 6, 26
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
biospace
Aug 5, 26
Attovia adds to biotech IPO momentum with $289M offering
biopharma dive
Aug 5, 26
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
fiercebiotech
Aug 5, 26
A COPD drug from China draws $115M in venture funding
biopharma dive
Aug 5, 26
Lilly drops another gene therapy trial from $1B Prevail buyout
fiercebiotech
Aug 5, 26
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
fiercebiotech
Aug 5, 26
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
Aug 4, 26
Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey
fiercebiotech
Aug 4, 26
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
fiercebiotech
Aug 3, 26
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
Jul 31, 26
Trump administration tries again to institute rebates in 340B
biopharma dive
Jul 31, 26
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
biospace
Jul 31, 26
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
Jul 31, 26
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
biopharma dive
Jul 31, 26
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
Jul 30, 26
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
endpoints
Jul 30, 26
Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
biospace
Jul 30, 26
Garijo's plan to revamp Sanofi: an R&D cleanup, more M&A and a China push
endpoints
Jul 30, 26
Takeda, Regeneron, Sanofi and Bristol Myers trim pipelines
endpoints
Jul 30, 26
Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
biospace
Jul 30, 26
Sanofi records €1B+ write-off, ends work on two immunology assets
endpoints
Jul 30, 26
Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
fiercebiotech
Jul 30, 26
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
← prev
page 4 of 8
next →
